6-(四氢吡喃氧基)己酸乙酯 | 32437-87-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 6-(四氢吡喃氧基)己酸乙酯
• 英文名称: ethyl 6-(tetrahydropyranyloxy)hexanoate
• 英文别名: Ethyl 6-(2-tetrahydropyranyloxy)hexanoate；ethyl 6-(oxan-2-yloxy)hexanoate
• CAS: 32437-87-9
• 化学式: C₁₃H₂₄O₄
• 分子量: 244.331
• InChiKey: ZEKNHYYXGFWGNI-UHFFFAOYSA-N

物化性质

• 沸点：
  107-110 °C(Press: 290 Torr)
• 密度：
  1.01±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(四氢吡喃氧基)己酸乙酯 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以100%的产率得到6-羟基己酸乙酯
  参考文献：
  名称：

  Cleavage of the THP protecting group under Pd/C-catalyzed hydrogenation conditions

  摘要：

  Alcohol and phenol THP or ethoxyethyl ether protecting groups may be cleaved in high yield under Pd/C-catalyzed hydrogenation conditions in EtOH, owing to the inadvertent presence of small quantities of HCl in the reaction mixture. MOM ethers are not cleaved under these conditions. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)01630-6
• 作为产物：
  描述：

  allyl ethyl (4-(tetrahydropyranyloxy)butyl)malonate 在 palladium diacetate 、 甲酸 、 三乙胺 、 三苯基膦 作用下， 以 1,4-二氧六环 为溶剂， 反应 7.0h， 以70%的产率得到6-(四氢吡喃氧基)己酸乙酯
  参考文献：
  名称：

  Facile transformation of substituted allyl malonates to monocarboxylic acids and esters by the reaction with ammonium formate catalyzed by palladium complexes

  摘要：

  DOI：

  10.1021/jo00283a044

文献信息

• Synergistic composition comprising PGF.sub.2.sub..alpha. and PGE.sub.2
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：US03978229A1

  公开（公告）日：1976-08-31

  A synergistic composition comprising as active ingredients a PGF.sub.2.sub..alpha. compound or its cyclodextrin clathrate thereof and a PGE.sub.2 compound or its cyclodextrin clathrate thereof, at a weight ratio of from about 1:0.33 to about 1:1.

  一种协同组合物，包含作为活性成分的PGF.sub.2.sub..alpha.化合物或其环糊精包合物以及PGE.sub.2化合物或其环糊精包合物，两者的重量比约为1:0.33至约1:1。
• 20-Hydroxy-prostaglandins
  申请人：Ono Pharmaceutical Company

  公开号：US04140712A1

  公开（公告）日：1979-02-20

  The present invention relates to 20-hydroxy prostaglandins of the formula: ##STR1## wherein A represents a grouping of the formula: ##STR2## and X represents ethylene or cis-vinylene and Y represents trans-vinylene, or X and Y each represent ethylene, R represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 12 carbon atoms, R.sup.1 , R.sup.2, R.sup.3, R.sup.4 and R.sup.5, which may be the same or different, each represent a hydrogen atom or a methyl or ethyl group, and n represents zero or an integer from 1 to 3 inclusive, and cyclodextrin clathrates of such acids and esters and, when R represents a hydrogen atom, the non-toxic salts thereof. These compounds exhibit characteristic prostaglandin activity.

  本发明涉及以下式的20-羟基前列腺素：##STR1##其中A代表以下式的分组：##STR2##X代表乙烯或顺式乙烯基，Y代表反式乙烯基，或者X和Y各代表乙烯基，R代表氢原子或含有1至12个碳原子的直链或支链烷基基团，R.sup.1，R.sup.2，R.sup.3，R.sup.4和R.sup.5，可以相同也可以不同，每个代表氢原子或甲基或乙基基团，n代表零或1至3之间的整数，并且这些酸和酯的环糊精包合物以及当R代表氢原子时的非毒性盐。这些化合物表现出特征的前列腺素活性。
• 16-Chloro-substituted prostaglandins and derivatives thereof
  申请人：Ono Pharmaceutical Company

  公开号：US04069387A1

  公开（公告）日：1978-01-17

  The present invention relates to compounds of the formula: ##STR1## wherein A represents a grouping of the formula: ##STR2## B represents a single bond or a straight- or branched-chain alkylene group containing from 1 to 9 carbon atoms, W represents ethylene or trans-vinylene, X represents ethylene or cis-vinylene, Y represents ethylene or trans-vinylene, R represents a hydroxymethyl group or a grouping of the formula --COOR.sup.4, in which R.sup.4 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 12 carbon atoms, R.sup.1 represents a hydrogen atom or a methyl or ethyl group, R.sup.2 represents a hydrogen atom or a methyl or ethyl group and R.sup.3 represents a hydrogen or chlorine atom or a hydroxy group and cyclodextrin clathrates of such alcohols, acids and esters and, when R.sup.4 in the formula --COOR.sup.4 represents a hydrogen atom, non-toxic salts thereof, and intermediates therefor. These compounds exhibit characteristic prostaglandin-like activity.

  本发明涉及以下结构的化合物：其中A代表以下结构的集合：B代表单键或含有1至9个碳原子的直链或支链烷基基团，W代表乙烯或反式-乙烯基，X代表乙烯或顺式-乙烯基，Y代表乙烯或反式-乙烯基，R代表羟甲基基团或--COOR.sup.4结构的集合，在该结构中R.sup.4代表氢原子或含有1至12个碳原子的直链或支链烷基基团，R.sup.1代表氢原子或甲基或乙基基团，R.sup.2代表氢原子或甲基或乙基基团，R.sup.3代表氢原子或氯原子或羟基，以及这些醇，酸和酯的环糊精包合物，当公式--COOR.sup.4中的R.sup.4代表氢原子时，其非毒性盐和其中间体。这些化合物具有特征性的前列腺素样活性。
• COMPOUNDS FOR SUSTAINED RELEASE OF ORALLY DELIVERED DRUGS
  申请人：GALLOP Mark A.

  公开号：US20080255073A1

  公开（公告）日：2008-10-16

  Disclosed are methods for providing sustained systemic blood concentrations of orally delivered drugs. Still further, disclosed are compounds and pharmaceutical compositions that are used in such methods.

  本发明公开了一种提供口服药物持续全身血液浓度的方法。此外，还公开了用于这种方法的化合物和药物组成物。
• A simple and mild esterification method for carboxylic acids using mixed carboxylic-carbonic anhydrides
  作者：Sunggak Kim、Jae In Lee、Youn Chul Kim

  DOI：10.1021/jo00205a004

  日期：1985.3